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Summary
The oncogenic BCR/ABL kinase activity induces and maintains chronic myelogenous leukemia (CML). We show here that,
in BCR/ABL-transformed cells and CML blast crisis (CML-BC) progenitors, the phosphatase activity of the tumor suppres-
sor PP2A is inhibited by the BCR/ABL-induced expression of the PP2A inhibitor SET. In imatinib-sensitive and -resistant
(T315I included) BCR/ABL+ cell lines and CML-BC progenitors, molecular and/or pharmacological activation of PP2A
promotes dephosphorylation of key regulators of cell proliferation and survival, suppresses BCR/ABL activity, and induces
BCR/ABL degradation. Furthermore, PP2A activation results in growth suppression, enhanced apoptosis, restored differ-
entiation, impaired clonogenic potential, and decreased in vivo leukemogenesis of imatinib-sensitive and -resistant BCR/
ABL+ cells. Thus, functional inactivation of PP2A is essential for BCR/ABL leukemogenesis and, perhaps, required for
blastic transformation.S I G N I F I C A N C E
A tight control of kinase and phosphatase activity is fundamental for normal cell growth, survival, and differentiation. Leukemia is
often associated with expression of oncoproteins with aberrant kinase activity. By contrast, PP2A, a phosphatase regulating many
cellular functions, is genetically inactivated in many types of cancer. Here, we show that PP2A activity is suppressed in blast crisis
but not chronic phase CML cells through the BCR/ABL-induced expression of its inhibitor, SET. Restoration of PP2A activity inhibits
BCR/ABL expression/activity, hence impairing wild-type and T315I BCR/ABL leukemogenesis. These findings establish an unexpected
link between an oncogenic kinase and a phosphatase with tumor suppressor activity and indicate that pharmacologic enhance-
ment of PP2A represents a possible therapeutic strategy for blast crisis and imatinib-resistant CML.Introduction
A tight control of kinase and phosphatase activity is fundamen-
tal for normal cell growth, survival, and differentiation (Hunter,
1995). Chronic myelogenous leukemia (CML) is the best exam-
ple for understanding how central the “reversible phosphoryla-
tion” process is in the regulation of normal hematopoiesis. In
fact, the deregulated tyrosine kinase activity of the BCR/ABL
oncoprotein induces and maintains the leukemic phenotype
and contributes to transition from an indolent “chronic phase”
(CML-CP) to the aggressive “blast crisis” (CML-BC) (Calabretta
and Perrotti, 2004) by recruiting and activating pathways that
transduce oncogenic signals leading to growth factor-indepen-
dent proliferation, increased survival, and altered differentiationCANCER CELL : NOVEMBER 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIEof hematopoietic progenitors (Calabretta and Perrotti, 2004;
Wong and Witte, 2004). Dependence on BCR/ABL expression
is not only a feature of CML-CP; in fact, BCR/ABL levels in-
crease during disease progression (Barnes et al., 2005; Elmaa-
gacli et al., 2000; Gaiger et al., 1995; Jamieson et al., 2004),
and sustained BCR/ABL expression in myeloid progenitors in-
duces phenotypic changes characteristic of CML-BC (Cala-
bretta and Perrotti, 2004). Accordingly, inhibition of BCR/ABL
kinase activity with imatinib mesylate is therapeutically effec-
tive not only in CML-CP (O’Brien et al., 2003) but also, albeit
temporarily, in CML-BC (Sawyers et al., 2002), in which resis-
tance and relapses are contingent upon BCR/ABL reactivation
(Shah and Sawyers, 2003).
In BCR/ABL-expressing myeloid progenitor cells, high levelsR INC. DOI 10.1016/j.ccr.2005.10.015 355
A R T I C L Eof BCR/ABL, like those observed in CML-BC, arrest differentia-
tion and enhance survival in part by enhancing the expression
and activity of specific RNA binding proteins (Iervolino et al.,
2002; Perrotti et al., 1998, 2002; Trotta et al., 2003). In particu-
lar, expression of hnRNP A1 is induced by BCR/ABL in a ki-
nase-dependent manner and increases in CML-BC (Iervolino
et al., 2002). In addition, hnRNP A1 mRNA export activity is
required for proliferation, survival, and tumorigenesis of acute
phase CML blasts and BCR/ABL+ myeloid precursor cell lines
(Iervolino et al., 2002).
In this study, we identified SET, a nucleus/cytoplasm-local-
ized phosphoprotein overexpressed in solid tumors and leuke-
mias (Carlson et al., 1998; Fornerod et al., 1995), as a novel
BCR/ABL target whose mRNA is associated with hnRNP A1
in Ph1 cells. Notably, SET is a potent inhibitor of the tumor
suppressors NM23-H1 (Fan et al., 2003) and protein phospha-
tase 2A (PP2A) (Li et al., 1996). The latter is a phosphatase that
regulates cell proliferation, survival, and differentiation (Jans-
sens and Goris, 2001; Wang et al., 2004) and whose loss of
function has been associated with cell transformation (Jans-
sens et al., 2005; Schonthal, 2001). We herein show that in
BCR/ABL+ cell lines and in patient-derived CML (CP and BC)
CD34+ cells, SET expression is enhanced by BCR/ABL and
increases during CML disease progression. This, in turn, re-
sults in progressive loss of PP2A tumor-suppressive activity.
Restoring PP2A activity in myeloid CML-BCCD34+ patient cells
and BCR/ABL+ cell lines impairs in vitro and in vivo BCR/ABL
leukemogenic potential by inducing inactivation and conse-
quent downregulation of the BCR/ABL oncoprotein itself. Thus,
the BCR/ABL-dependent SET-mediated inhibition of PP2A tu-
mor-suppressive activity may, therefore, favor CML disease
progression.
Results
SET association with hnRNP A1 and effect of BCR/ABL
on SET expression
Using Ribonomics (Tenenbaum et al., 2002), SET mRNA was
found specifically associated with cytoplasmic hnRNP A1 in
Ph1 K562 cells (data not shown). To validate the SET mRNA-
hnRNP A1 association, RT-PCR was carried out on anti-hnRNP
A1- and anti-FLAG-immunoprecipitated cytoplasmic mRNAs
using a pair of primers spanning a 224 bp segment of the hu-
man SET cDNA. As shown, high levels of SET mRNA transcripts,
similar to those present in the mRNP-enriched mRNA fraction,
were clearly detectable in association with hnRNP A1 (Figure 1A).
In growth factor-independent BCR/ABL-expressing 32Dcl3
myeloid precursors, SET mRNA and protein levels correlated
with those of hnRNP A1 and BCR/ABL (Figure 1B). Similarly,
SET was upregulated in the doxycycline-treated (2 g/ml; 3
days) TonB210.1 lymphoid precursors in which BCR/ABL ex-
pression is tetracycline inducible (Figure 1B, lanes 6 and 7). In
addition, treatment (24 hr, 1 M) with the ABL tyrosine kinase
inhibitor imatinib markedly impaired SET mRNA and protein ex-
pression in both 32D-BCR/ABL and K562 cells (Figure 1B,
lanes 2 and 5). Consistent with these data, SET and hnRNP
A1 levels were increased upon BCR/ABL expression in CD34+
mouse bone marrow cells (BMC) (Figure 1B, lanes 8 and 9).
SET protein levels correlated with BCR/ABL activity and
were higher in myeloid CML-BCCD34+ (n = 3) than CML-
CPCD34+ (n = 3) patient-derived BMC, and in CML-CPCD34+ pa-356tient cells than in CD34+ cells from normal donors (NBM) (n =
3) (Figure 1C, right panel). Similarly, SET expression was higher
in myeloid CML-BC (n = 9) than in CML-CP (n = 9) patient-
derived mononuclear marrow cells (Figure 1C, left and middle
panels) and correlated with that of BCR/ABL and hnRNP A1 in
paired CML-CP and CML-BC samples (Figure 1C, left panel).
Moreover, treatment of CML-BCCD34+ cells with imatinib de-
creased SET levels (Figure 1C, lanes 5 and 6), further indicating
that BCR/ABL activity is responsible for SET upregulation in
CML-BC. As expected, SET expression was reduced in cyto-
kine-deprived (12 hr) 32Dcl3 and NBMCD34+ cells (see Figure
S1A in the Supplemental Data available with this article online)
but not in cytokine-deprived BCR/ABL+ cells.
Relevance of increased SET expression in BCR/
ABL-transformed cells: Role of PP2A
Reportedly, SET is a potent inhibitor of the multimeric serine-
threonine phosphatase PP2A (Li et al., 1996). In 32D-BCR/ABL
and in CML-BCCD34+ patient cells (Figure 2A, left panel) and
K562 cells (data not shown), levels of the PP2A catalytic sub-
unit (PP2Ac) were not affected by BCR/ABL expression and/or
kinase activity. By contrast, levels of the PP2A structural sub-
unit PR65/A were enhanced in 32D-BCR/ABL cells and corre-
lated with increased levels of PP2Ac phosphorylation on tyro-
sine 307 (Figure 2A, right panel) which, as reported, inhibits
PP2A activity (Chen et al., 1992). Accordingly, PP2A activity
was reduced by 83% in 32D-BCR/ABL compared to parental
32Dcl3 cells, and restored to normal levels in imatinib-treated
(1 M, 24 hr) 32D-BCR/ABL cells (Figure 2B). As expected,
imatinib did not rescue PP2A activity in imatinib-resistant
BaF3p210T315I cells (Figure 2B). Furthermore, PP2A activity
was also reduced by 94% and 52% in the CD34+ fraction of
myeloid CML-BC and CML-CP cells, respectively, compared
to the CD34+ fraction of NBM cells (Figure 2B).
To determine whether SET upregulation is responsible for
suppression of PP2A activity, we interfered with SET expres-
sion by infecting parental 32Dcl3, 32D-BCR/ABL, and K562
cells with a pSuper.retro-shSET construct carrying a short hair-
pin RNA (shRNA) targeting nucleotides 120–138 of the SET
cDNA. Expression of SET shRNA downregulated levels of SET,
but not those of the other PP2A regulator pp32/I1PP2A (Figure
2B, inset) and restored PP2A activity to levels similar to those
of 32Dcl3 or imatinib-treated 32D-BCR/ABL cells (Figure 2B)
without affecting PP2Ac expression (Figure 2A). Interestingly,
levels of PP2AcTYR307 were markedly reduced upon imatinib
treatment and SET downregulation (Figure 2C). Moreover, in
BCR/ABL-expressing cells, expression of ectopic HA-PP2Ac
strongly increased PP2A activity (Figure 2B) and diminished
PP2AcTYR307 levels (Figure 2C), while no effects were observed
in vector-transduced cells (data not shown). PP2A activity also
was not significantly affected in parental 32Dcl3 cells by SET
shRNA expression (Figure S1B). By contrast, ectopic FLAG-
SET expression augmented PP2ATYR307 levels in HA-PP2Ac-
expressing BCR/ABL cells (Figure 2C) and lowered PP2A activ-
ity in 32Dcl3 cells to levels similar to those of 32D-BCR/ABL
cells (Figure S1B). Accordingly, SET was associated with
PP2Ac in 32D-BCR/ABL and CML-BCCD34+ cells but not in
32Dcl3 cells (Figure S2C).
Because several PP2A targets are essential for BCR/ABL
leukemogenic potential, we assessed the importance of the
SET-PP2A interplay in the regulation of the BCR/ABL signalingCANCER CELL : NOVEMBER 2005
A R T I C L EFigure 1. Effect of BCR/ABL on SET expression
A: RT-PCR shows association of SET mRNA with hnRNP A1 in mRNP-enriched lysates, anti-FLAG-IP (negative control), and anti-hnRNP A1-IP from K562 cells.
B: SET RNA (first row) and protein (third row) levels in 32Dcl3, untreated and imatinib-treated 32D-BCR/ABL and K562 cells, doxycycline (DOX)-treated or
untreated BCR/ABL-inducible TonB210.1 cells, and vector- and BCR/ABL-infected mouse CD34+/lin− bone marrow cells (BMC). hnRNP A1, BCR/ABL, and
Grb2 protein levels were detected as control.
C: Left panel: SET, hnRNP A1, and BCR/ABL protein levels in mononuclear marrow (BM) cells from two paired CML-CP and -BC patient samples, and in
untreated and imatinib-treated CML-BCCD34+ cells; middle panel: scatter plots show SET protein levels in BM cells from seven CML-CP and -BC patient
specimens (p = 0.003; Wilcoxon rank sum test); right panel: graph shows SET (light bars) and BCR/ABL (dark bars) protein expression (expressed as mean ±
SE of densitometric units after normalization with Grb2 levels) in the CD34+ fraction from bone marrow of healthy donors (NBM) (n = 3), CML-CP (n = 3),
and CML-BC (n = 3) patients (NBM versus CML-CP, p = 0.03; CML-CP versus CML-BC, p = 0.004; paired samples t test).network by determining the levels and/or activity of distinct
BCR/ABL and PP2A targets in SET shRNA- and HA-PP2Ac-
expressing 32D-BCR/ABL cells. In these cells, enhanced PP2A
activity induced by imatinib treatment, by inhibition of SET, and
to a greater extent, by PP2Ac overexpression decreased levels
of hyperphosphorylated Rb, suppressed Myc expression, and
STAT5, ERK1/2, Akt, BAD, and Jak2 phosphorylation (Figure
2C, lanes 2–4) without affecting their expression (Figure S2D).
Consistent with the role of PP2A as a potent BCR/ABL antago-
nist, transduction of FLAG-SET in HA-PP2A-expressing 32D-
BCR/ABL cells restored the expression/activity of these BCR/
ABL targets (Figure 2C, lane 5).
BCR/ABL is a target of PP2A activity
Expression of SET shRNA or HA-PP2A in 32D-BCR/ABL cells
suppressed p210BCR/ABL tyrosine phosphorylation and expres-
sion (Figure 3A, lanes 2 and 3). This effect, also observed inCANCER CELL : NOVEMBER 2005K562 cells (data not shown), was dependent on enhanced
PP2A phosphatase activity because both SET overexpression
and treatment with the phosphatase inhibitor okadaic acid
(0.25 nM; 1 hr) and calyculin A (data not shown), used at con-
centrations that inhibit PP2A but not other phosphatases (Say-
dam et al., 2003), restored BCR/ABL activity and expression in
HA-PP2Ac-transduced (Figure 3A, lanes 4 and 7) and in SET
shRNA-transduced (data not shown) cells. Conversely, exposure
(18–24 hr) of BCR/ABL+ cell lines and CML-BCCD34+ marrow
blasts to the PP2A activators (Feschenko et al., 2002) forskolin
(40 M), butyryl-forskolin (water soluble), or 1,9-dideoxy-forskolin
(lacks adenylate cyclase-activating function) enhanced PP2A ac-
tivity (Figure S3A), abolished BCR/ABL phosphorylation, and to
a different extent, induced downregulation of BCR/ABL (Figure
3B) with EC50 of 18 M and 25 M in imatinib-sensitive and
-resistant cells, respectively. Interestingly, the cAMP inducer
theophylline (100 M; 24 hr) did not affect BCR/ABL expres-357
A R T I C L EFigure 2. Effect of BCR/ABL on PP2A activity
A: Left panel: protein levels of PP2Ac and Grb2 in the following: 32Dcl3, untreated and imatinib-treated 32D-BCR/ABL and primary CML-BCCD34+ marrow
cells, and SET shRNA-expressing 32D-BCR/ABL; right panel: levels of PR65/A, PP2Ac, PP2AcTYR307, and Grb2 in 32Dcl3 and 32D-BCR/ABL cells.
B: PP2A phosphatase assay in 32Dcl3, 32D-BCR/ABL, BaF3-p210(T315I), CML-BCCD34+, CML-CPCD34+, and NBMCD34+cells, and in BCR/ABL cells expressing the
SET shRNA or HA-PP2Ac or treated with imatinib. Bars represent the PP2A activity (expressed as mean ± SE of three independent experiments performed
with the indicated cell lines, and with NBMCD34+ (n = 3), CML-CPCD34+ (n = 3), and CML-BCCD34+ (n = 3) cells. Inset: effect of the SET shRNA on SET and pp32
protein levels; representative of two experiments performed in triplicate.
C: Effect of imatinib and of ectopic SET shRNA, HA-PP2Ac, or HA-PP2A/FLAG-SET expression on the levels of the indicated BCR/ABL and PP2A targets in
32D-BCR/ABL cells. Endogenous and ectopic SET and PP2Ac and PP2AcTYR307 levels are shown (rows 8–12).sion/activity, and the PKA inhibitor myristoylated-PKI(14-22)-
amide (4 M; 24 hr) did not inhibit the forskolin-induced BCR/
ABL downregulation (Figure 3C).
PP2A-dependent mechanisms regulating BCR/ABL
expression/activity
To determine whether PP2A-induced BCR/ABL dephosphory-
lation renders BCR/ABL more susceptible to proteolysis, we
treated PP2A-expressing 32D-BCR/ABL cells with the protea-
some inhibitor ALLN (25 M; 8 hr). As shown, ALLN restored
BCR/ABL expression and, as expected, did not prevent PP2A-
induced BCR/ABL tyrosine dephosphorylation (Figure 4A),
which precedes and, likely, is required for its degradation.
In anti-Abl Western blot on anti-PP2Ac immunoprecipitates,
we found p210BCR/ABL associated with PP2Ac in SET shRNA-
expressing but not in parental 32D-BCR/ABL cells (Figure 4B,
lanes 3 and 4). Interestingly, the BCR/ABL-associated SHP-1
tyrosine phosphatase (Liedtke et al., 1998) was also present in358the same PP2A-containing complex (Figure 4B), and restored
BCR/ABL phosphorylation was observed after treatment of
SET shRNA- and HA-PP2A-expressing 32D-BCR/ABL cells
with sodium stibogluconate (SS) (Figure 4C), a specific SHP-1
inhibitor (Pathak and Yi, 2001). Furthermore, the PP2A activa-
tor forskolin (40 M; 18 hr) inhibited BCR/ABL expression and
tyrosine phosphorylation and decreased by w70% the clono-
genic potential of BCR/ABL-transduced wild-type (+/+) but not
SHP-1-deficient (Kozlowski et al., 1993) (−/−) moth eaten viable
CD34+ mouse marrow cells (Figures 4D and 4E). Note that the
clonogenicity of SHP-1−/− cells was higher than that of wild-
type cells (Figure 4E).
Increased PP2A activity suppresses BCR/ABL
oncogenic potential in vitro
To assess whether increased PP2A activity affects proliferation
and survival of BCR/ABL-transformed cells, parental, SET
shRNA-expressing, and HA-PP2A-expressing 32D-BCR/ABLCANCER CELL : NOVEMBER 2005
A R T I C L EFigure 3. Effect of PP2A on BCR/ABL kinase activity and expression
A: p210BCR/ABL activity (αPY) and expression (α-Abl) in 32D-BCR/ABL and in
its derivative SET shRNA-, HA-PP2A-, and HA-PP2A/FLAG-SET-expressing cell
lines, and in HA-PP2A 32D-BCR/ABL cells treated with okadaic acid.
B: Effect of the PP2A activators forskolin, butyryl-forskolin, and 1,9-dideoxy-
forskolin on BCR/ABL activity and expression in primary CML-BC and ima-
tinib-sensitive and -resistant BCR/ABL cell lines.
C: Effects of forskolin, theophylline, and the PKA inhibitor myristoylated PKI
(14-22) amide on BCR/ABL expression/activity. Grb2 levels were detected
as controls.CANCER CELL : NOVEMBER 2005cells were grown in the presence or absence of IL-3. In IL-3-
containing medium, there were no differences in the growth of
32D-BCR/ABL and its derivative cell lines (data not shown).
Between 36 and 48 hr after IL-3 withdrawal, an w60% de-
crease in the number of viable cells was visible in SET shRNA-
and HA-PP2A-expressing 32D-BCR/ABL when compared to
parental cultures (Figure 5A). Moreover, SET shRNA- and, to a
greater extent, HA-PP2A-expressing 32D-BCR/ABL cells un-
derwent granulocytic differentiation upon exposure (9–12 days)
to G-CSF (Figure 5B). As expected, forced FLAG-SET expres-
sion conferred a proliferation advantage and inhibited differ-
entiation of HA-PP2A-expressing cells (Figures 5A and 5B).
Similarly, reduced viability and spontaneous erythroid differen-
tiation, observed in K562 cells ectopically expressing SET
shRNA or HA-PP2A, was counteracted by SET overexpression
(data not shown).
Note that SET overexpression did not confer cytokine-inde-
pendent growth and slightly enhanced proliferation of 32Dcl3
cells (Figure S1C). Similarly, SET downregulation in 32Dcl3
cells did not alter IL-3-dependent proliferation, consistent with
the observation that SET shRNA expression did not affect
PP2A activity in 32Dcl3 cells (Figures S1B and S1C).
The importance of suppression of PP2A activity for BCR/
ABL leukemogenesis was further investigated by assessing the
colony-forming ability of SET shRNA-, HA-PP2A-, and HA-
PP2A/FLAG-SET-expressing BCR/ABL+ cell lines. Similarly,
CML-BCCD34+ patient cells transduced with a MigRI-HA-
PP2Ac or insert-less retrovirus were GFP sorted and plated in
methylcellulose in the presence of cytokines. 32D-BCR/ABL
(Figure 5C) and K562 (data not shown) cells formed high num-
bers of colonies in the absence of growth factors (Figure 5C).
By contrast, the colony-forming ability of SET shRNA- and HA-
PP2A-expressing cells was markedly suppressed (60%–65%
inhibition) (Figure 5C), and the colony size was much smaller
than that of parental cells (data not shown). Consistent with its
role as a PP2A inhibitor, SET overexpression completely res-
cued the cytokine-independent colony-forming ability of HA-
PP2A-expressing BCR/ABL cell lines (Figure 5C). Accordingly,
HA-PP2Ac expression restored PP2A activity back to normal
levels (Figure 5C, inset in right panel) and reduced by w90%
the clonogenic potential of CML-BCCD34+ cells (Figure 5C,
right panel).
Antileukemic effects of forskolin in primary CML-BCCD34+
cells and in imatinib-sensitive and -resistant
BCR/ABL cell lines
To investigate whether inhibition of BCR/ABL activity/expres-
sion by pharmacological activation of PP2A (Figure 3B) corre-
lates in vitro with impaired BCR/ABL leukemogenic potential,
32Dcl3, NBMCD34+, 32D-BCR/ABL, K562, the imatinib-resis-
tant 32D-p210Y253H and BaF3-p210T315I, and CML-BCCD34+
patient cells were treated with the PP2A activator forskolin (40
M; 96 hr). Forskolin strongly augmented PP2A phosphatase
activity in all BCR/ABL cell lines and primary CML-BCCD34+
blasts (Figure 6A) but not in 32Dcl3 (Figure S1B) or in
NBMCD34+ cells (Figure 6A). While untreated cells grew with
normal kinetics (Figure 6A, light bars), forskolin treatment re-
sulted in marked suppression of cell growth and enhanced
apoptosis (Figure 6A, dark bars) of cytokine-deprived imatinib-
sensitive and -resistant BCR/ABL+ cell lines and of IL-3/IL-6/
Flt-3 ligand/c-Kit ligand-cultured CML-BCCD34+ patient cells.359
A R T I C L EFigure 4. PP2A-dependent regulation of BCR/ABL activity/expression
A: p210BCR/ABL activity and expression in parental and untreated or ALLN-treated HA-PP2A-expressing 32D-BCR/ABL cells. B: Association of PP2A with BCR/
ABL and SHP-1 in parental and SET shRNA-expressing 32D-BCR/ABL cells. C: Effect of the SHP-1 inhibitor sodium stibogluconate (SS) on BCR/ABL activity in
parental and HA-PP2A- and SET shRNA-expressing 32D-BCR/ABL cells. Effect of forskolin on BCR/ABL expression/phosphorylation (D) and clonogenicity (E)
of BCR/ABL-expressing wild-type (+/+) and SHP-1-deficient “viable moth eaten” (−/−) CD34+ mouse bone marrow cells (BMC). Bars represent the mean ±
SE of the colony number from four clonogenic assays with untreated and forskolin-treated BCR/ABL-expressing wild-type and viable moth eaten CD34+
marrow cells (untreated+/+ versus drug-treated+/+, p = 0.003; untreated−/− versus drug-treated−/− p = 0.206; paired samples t test).As expected, the effect of imatinib (1 M) paralleled that of
forskolin in imatinib-sensitive, but not resistant, BCR/ABL+
cells (Figure 6A, red lines). Note that, after 48 hr of forskolin
treatment, the percentage of apoptosis (annexin V+ cells) in
BCR/ABL+ cell lines and primary CML-BC cells was R80%
and R95%, respectively (Figure S3B). By contrast, forskolin
treatment neither inhibited IL-3-dependent growth nor induced
apoptosis of 32Dcl3 cells (Figures S1C and S3B). Notably, in
primary NBMCD34+ cells, forskolin partially inhibited cytokine-
dependent proliferation to the same extent as imatinib (Figure
6A) without inducing apoptosis (Figure S3B). Indeed, cell cycle
analysis of forskolin-treated (24 hr) NBMCD34+ cells revealed an
increased number of cells in G1 and a reduced number in S
phase (data not shown).
Restored differentiation was another feature exhibited by for-
skolin-treated cells; after 9–12 days of exposure to G-CSF and
forskolin, cell death was evident in 30%–40% of both imatinib-
sensitive 32D-BCR/ABL and -resistant 32D-p210Y253H cell cul-
tures, whereas the remaining 60%–70% showed signs (e.g.,
segmented nuclei) of terminal neutrophilic differentiation (Fig-
ure 6B, right panels). By contrast, cells exposed only to G-CSF
remained blasts and proliferated (Figure 6B, left panels). Seem-
ingly, forskolin-treated K562 cells underwent erythroid differen-
tiation (Figure 6B).360Regardless of the degree of responsiveness to imatinib, both
sensitive and resistant BCR/ABL+ cell lines showed inhibition
(average: 75%) of clonogenic potential when exposed to for-
skolin (Figure 6C). Accordingly, forskolin strongly abolished
(80%–90% inhibition) the ability of primary CML-BCCD34+ and
CML-CPCD34+ marrow cells to form IL-3-derived colonies in
semisolid medium (Figure 6C). In addition, the colonies derived
from forskolin-treated cells were also reduced in size (data not
shown), thus resembling the effects of PP2A overexpression
on the colony-forming ability of BCR/ABL+ cells. Moreover,
levels of BCR/ABL phosphorylation in residual colonies derived
from forskolin-containing cultures were comparable to those
from colonies of untreated BCR/ABL cells (data not shown),
suggesting that a decrease in forskolin activity occurring in 15
days of semisolid culture accounts for the presence of resid-
ual colonies.
Although forskolin did not induce apoptosis of NBMCD34+
cells, a 40%–50% decrease in their IL-3-dependent clonoge-
nicity was observed upon exposure to forskolin (Figure 6C).
Interestingly, the PP2A activator 1,9-dideoxy forskolin, which
lacks adenylate cyclase-activating function, had only a modest
(%15%) effect on cytokine-driven colony formation of CD34+
myeloid progenitors, whereas it induced a 85%–90% decrease
in the clonogenic potential of CML-BCCD34+cells (Figure 6C).CANCER CELL : NOVEMBER 2005
A R T I C L EFigure 5. In vitro effects of PP2Ac overexpression
A: Effect of ectopic SET shRNA, HA-PP2A, and HA-PP2A/FLAG-SET expression on the cytokine-independent growth of 32D-BCR/ABL. Each point of the graph
represents the mean ± SE of the number of viable cells from three independent experiments.
B: May-Grunwald/Giemsa staining of cytospins of G-CSF-treated (9–12 days) 32D-BCR/ABL and derivative cell lines.
C: Growth factor-independent colony-forming ability of parental cells and SET shRNA-, HA-PP2A-, and HA-PP2A/FLAG-SET-expressing 32D-BCR/ABL, and
effect of ectopic PP2Ac expression on the IL-3- and G-CSF-driven colony formation of CML-BCCD34+ (dark bars). Red bars indicate colonies from vector-
transduced cells. Bars represent the mean ± SD of three independent experiments (primary cells: n = 2). Inset: expression of ectopic PP2Ac in GFP+ CML-
BCCD34+ and PP2A activity in MigRI- and MigRI-HA-PP2Ac-transduced CML-BCCD34+, and in CD34+ normal marrow cells (NBM).Increased PP2A activity impairs in vivo
BCR/ABL leukemogenesis
To investigate the effect of PP2A on BCR/ABL tumorigenesis,
SCID mice (n = 5 per group) were injected subcutaneously with
parental cells or SET shRNA-, HA-PP2Ac-, or HA-PP2A/FLAG-
SET-expressing 32D-BCR/ABL cells. 32D-BCR/ABL and 32D-
BCR/ABL-HA-PP2A/FLAG-SET cells formed tumors (incidence:
5/5) in 6–7 days, whereas tumors from SET shRNA-expressing
32D-BCR/ABL cells were palpable (incidence: 5/5) only after
10–12 days postinjection (Figure 7A). By contrast, tumors from
HA-PP2A-expressing 32D-BCR/ABL cells were at most barely
palpable (incidence: 3/5) and, at 15 days postinjection, weighedCANCER CELL : NOVEMBER 200586%–90% less than the tumors derived from parental or HA-
PP2A/FLAG-SET-expressing 32D-BCR/ABL cells (Figure 7A).
Likewise, a 75% decrease in tumor mass was observed in mice
injected with SET shRNA-expressing 32D-BCR/ABL cells.
To determine if forskolin (LD50i.p. = 67 mg/kg) can attenuate
BCR/ABL leukemogenesis, SCID mice were intraperitoneally
(i.p.) treated with forskolin (4 mg/kg) 1 hr prior to and 7 days
after the intravenous (i.v.) injection of 32D-BCR/ABL cells (5 ×
105 cells/mouse) and compared with mice injected either with
cells or with forskolin only. Four weeks later, various organs
obtained from untreated, treated, and control groups were
evaluated by visual inspection and light microscopy. Mice in-361
A R T I C L EFigure 6. In vitro effects of forskolin on BCR/ABL oncogenic potential
A: Effect of the PP2A activator forskolin (dark bars) and of imatinib (red lines) on the growth of imatinib-sensitive and -resistant BCR/ABL+ cell lines and of
primary CML-BCCD34+ (n = 2) and NBMCD34+ (n = 2) cells; untreated cells (light bars). Effect of forskolin on PP2A activity is shown below each graph. Viable
cells and phosphatase activity in untreated and drug-treated cell lines and primary cells (n = 2) are expressed as mean ± SE of three independent experi-
ments.
B: May-Grunwald/Giemsa staining of G-CSF-treated 32D-BCR/ABL and imatinib-resistant 32D-p210Y253H cells; o-Dianisidine staining of untreated and for-
skolin-treated (48 hr) K562 cells.
C: Methylcellulose colony formation (expressed as mean ± SE of the colony number from three clonogenic assays) of untreated (red bars), forskolin-treated
(black bars), and 1,9-dideoxy-forskolin-treated (yellow bars) imatinib-sensitive and -resistant BCR/ABL cell lines, and cytokine-driven colony formation of
primary CML-BCCD34+ (n = 2), CML-CPCD34+ (n = 2), and normal (NBM) (n = 2) CD34+ cells.jected with parental 32D-BCR/ABL cells (n = 3) showed mas-
sive splenomegaly, whereas morphology of spleens from for-
skolin-treated 32D-BCR/ABL-injected mice (n = 3) resembled
that of control age-matched (n = 2) or forskolin-only (n = 2)
treated mice (Figure 7B). Hematoxylin/eosin-stained sections
of spleen, marrow, and liver of vehicle-treated 32D-BCR/ABL-
injected mice showed extensive infiltration of blasts with a low
degree of myeloid maturation typical of an overt acute myeloid
leukemia-like process (Figure 7B). In contrast, histopathology362of organs from the forskolin-treated 32D-BCR/ABL-injected
group (Figure 7B) was similar to that of the age-matched and
forskolin-injected control groups. Consistent with these find-
ings, the survival of forskolin-treated mice injected with 32D-
BCR/ABL cells was significantly longer (median: 8 weeks) than
that of mice injected with cells only (median: 4 weeks) (Figure
7C). At 15 weeks postinjection, 40% of forskolin-treated cell-
injected mice and 100% of control mice that received only for-
skolin were still alive with no sign of toxic side effects (dataCANCER CELL : NOVEMBER 2005
A R T I C L EFigure 7. In vivo effects of PP2A activation on wild-type and T315I BCR/ABL leukemogenesis
A: Tumors in SCID mice arising from subcutaneous injection of parental and derivative 32D-BCR/ABL cell lines. Latency time, incidence, and tumor weight
(mean ± SD) were calculated. (p < 0.01; Kruskal-Wallis test). B (top) and D: Representative visual analysis of spleens of untreated and drug-treated mice
injected or not injected with BCR/ABL+ cells. B (bottom): Hematoxylin/eosin staining of tissue sections from spleen, marrow, and liver. C: Effect of forskolin
on survival of SCID mice i.v. injected with 32D-BCR/ABL cells. Estimate survival probabilities were calculated by the Kaplan-Meier method (overall: p <
0.001; 32D-BCR/ABL versus 32D-BCR/ABL + forskolin: p < 0.001; log-rank test). E: Effect of 1,9-dideoxy forskolin on BCR/ABL(T315I)-mediated leukemogenesis.
SCID mice were treated 1–8 and 12–18 weeks after i.v. injection with 5 × 105 cells. Mice injected with cells or drug only served as controls. Survival probability
was calculated by the Kaplan-Meier method (p < 0.0001; log-rank test). F: Nested RT-PCR for BCR/ABL indicates the presence of 32D-BCR/ABL(T315I) cells
in peripheral blood of untreated and drug-treated mice. The last two lanes (negative and positive control, respectively) show nested RT-PCR performed
with RNA from blood of mice treated with drug only and from K562:32Dcl3 cells. Detection of GAPDH mRNA was used as control. Red dots indicate the
time of drug injection.CANCER CELL : NOVEMBER 2005 363
A R T I C L Enot shown). By contrast, modest to severe splenomegaly and
leukemic infiltration of hematopoietic organs were evident in
drug-treated BCR/ABL mice that died 5 or more weeks after
cell injection (data not shown).
In similar experiments, 26 SCID mice were i.v. injected (5 ×
105 cells/mouse) with 32D-BCR/ABL cells expressing the ima-
tinib-, AMN107-, and BMS354825-resistant T315I BCR/ABL
mutant. After 8 days, treatment with 1,9-dideoxy forskolin (8
mg/kg/week; i.p.; LD50 = 68 mg/kg) was initiated on 13 mice
upon determining the presence of circulating BCR/ABL+ cells
by nested RT-PCR-mediated detection of BCR/ABL transcripts
in the peripheral blood (Figure 7F, first panel). After 4 weeks of
treatment, drug-treated leukemic mice were all alive and BCR/
ABL negative (Figures 7E and 7F), whereas only 3 untreated
leukemic mice were alive but appeared lethargic and were
BCR/ABL+ (Figure 7F, second panel). Thus, a representative
sample of each group of mice was sacrificed, and various or-
gans were evaluated for signs of leukemia. Splenomegaly (Fig-
ure 7D) and infiltration of hematopoietic organs (data not
shown) was observed in mice injected with T315I cells. By con-
trast, organ infiltration (data not shown) and splenomegaly
were not present in drug-treated cell-injected mice (Figure 7D).
Because 70% of these mice were alive after 7 weeks of treat-
ment, administration of the drug was suspended (Figure 7E).
Unexpectedly, 20% of mice relapsed and died of an acute leu-
kemia-like disease process within 4 weeks from the end of
treatment (Figure 7E), and the remaining 50% tested BCR/
ABL+ (Figure 7F, third panel). After 4 weeks from restarting ther-
apy, 100% of treated mice (50% of cell-injected mice) became
BCR/ABL negative and were alive 18 weeks after cell injection
with no signs of toxic side effects (Figure 7E) like the control
age-matched or drug only-treated mice.
Discussion
Although the mechanisms responsible for CML disease pro-
gression are still largely unclear, growing evidence suggests
that the phenotype of CML-BC cells depends on the un-
restrained activity of BCR/ABL and on the genetic or functional
inactivation of genes with tumor suppressor activity (Calabretta
and Perrotti, 2004). Here, we report that the phosphatase activ-
ity of the tumor suppressor PP2A (Janssens et al., 2005) is
modestly affected in CML-CPCD34+ progenitors but markedly
impaired in myeloid CML-BCCD34+ cells. We demonstrated that
PP2A inactivation results from increased expression of SET, a
physiological inhibitor of PP2A (Li et al., 1996), which is in-
duced by BCR/ABL in a dose- and kinase-dependent manner
and, like BCR/ABL (Barnes et al., 2005; Elmaagacli et al., 2000;
Gaiger et al., 1995; Jamieson et al., 2004), progressively in-
creases during transition to blast crisis. In fact, imatinib treat-
ment and SET downregulation restored PP2A activity back to
normal levels. Interestingly, BCR/ABL might also inactivate
PP2A by inducing Jak2-dependent (Yokoyama et al., 2001)
and/or src-dependent (Chen et al., 1992) PP2Ac phosphoryla-
tion on tyrosine 307. Indeed, a portion of PP2Ac is phosphory-
lated on tyrosine 307 in BCR/ABL-expressing cells, and
PP2ATYR307 levels decrease upon SET downregulation or inhi-
bition of BCR/ABL activity. Thus, it is possible that BCR/ABL
also affects the ability of PP2A to reactivate itself by auto-
dephosphorylation (Chen et al., 1992) and/or that the SET/
PP2A association favors the recruitment of a BCR/ABL-acti-364vated tyrosine kinase that inhibits PP2A through phosphory-
lation of the PP2Ac tyrosine 307. Alternatively, SET overex-
pression and src and/or Jak2 activity might independently
contribute to PP2A inactivation in BCR/ABL cells. Interestingly,
the increased expression of the PP2A subunit PR65/A ob-
served in BCR/ABL+ cells may also contribute to PP2A inacti-
vation, as PR65/A overexpression could sequester the catalytic
or variable subunits or act as a PP2Ac inhibitor (Kamibayashi
et al., 1992; Wera et al., 1995). Suppression of PP2A activity
appears to be a common event in malignant transformation;
in fact, mutations in the genes encoding the β-isoform of the
structural PP2AA and some regulatory PP2AB subunits have
been found in several human cancers (Janssens et al., 2005).
Moreover, cellular transformation by the SV40 viral oncoprotein
small t Ag requires inactivation of PP2A (Yang et al., 1991), and
PP2Ac overexpression reduces Ha-RAS-induced cell trans-
formation (Baharians and Schonthal, 1999).
The tumor-suppressing activity of PP2A depends on its abil-
ity to interact with and dephosphorylate several factors impli-
cated in the regulation of cell cycle progression, proliferation,
survival, and differentiation (Sontag, 2001). Remarkably, sev-
eral targets are shared by BCR/ABL kinase and PP2A phos-
phatase. Among these, expression and/or activity of the PP2A
substrates Myc, STAT5, MAPK, Akt, BAD, and Rb (Avni et al.,
2003; Chiang et al., 2003; Gomez and Cohen, 1991; Sato et
al., 2000; Yeh et al., 2004; Yokoyama et al., 2001) are either
essential for BCR/ABL leukemogenesis or have been found al-
tered in CML-BC (Calabretta and Perrotti, 2004; Cortez et al.,
1997). In 32D-BCR/ABL cells, inhibition of SET expression and,
to a greater extent, forced expression of PP2Ac led to inhibition
of MAPK, STAT5 and Akt phosphorylation, decreased Myc ex-
pression, and increased levels of proapoptotic BAD. Since ec-
topic SET expression antagonized the effects of exogenous
PP2A, it is possible that, in CML-BC progenitors, SET-depen-
dent suppression of PP2A activity represents one of the main
mechanisms used by BCR/ABL to prevent inactivation of mito-
genic and survival signals. The importance of PP2A inhibition
for CML disease progression is also supported by the ability of
PP2A to induce Rb dephosphorylation (Avni et al., 2003) and
to suppress Jak2 kinase, which was found activated in CML-
BC (Xie et al., 2002).
By using chemical inhibitors and activators of PP2A and by
interfering with the SET/PP2A interplay (i.e., PP2Ac overex-
pression, SET knockdown), we provide evidence that BCR/
ABL is a bona fide target of PP2A in imatinib-sensitive and
-resistant BCR/ABL cell lines and in CML-BCCD34+ patient
cells. In fact, the ability of PP2A to markedly reduce BCR/ABL
tyrosine phosphorylation and expression is consistent with its
capacity to trigger inactivation and induce proteolysis of other
oncogenic tyrosine kinases (i.e., v-src) (Yokoyama and Miller,
2001). Mechanistically, downregulation of BCR/ABL levels in-
duced by ectopic PP2Ac expression depends on increased
proteasome degradation of nonphosphorylated BCR/ABL pro-
tein that was found physically associated to active PP2A and
SHP-1 tyrosine phosphatase. By using a specific SHP-1 inhibi-
tor and BCR/ABL-transduced SHP-1-decifient CD34+ marrow
cells, we demonstrated that the PP2A-induced BCR/ABL de-
phosphorylation and degradation are mediated by SHP-1. Be-
cause SHP-1 associates with BCR/ABL and its tyrosine phos-
phatase activity counteracts BCR/ABL leukemogenic potential
(Liedtke et al., 1998; Lim et al., 2000), it is likely that PP2ACANCER CELL : NOVEMBER 2005
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phorylates BCR/ABL and makes it prone to proteasome-
dependent proteolysis. Accordingly, we showed that loss of
SHP-1 abolished the inhibitory effects of PP2A activation on
BCR/ABL-dependent clonogenic potential. Restoration of PP2A
activity back to normal levels via SET downregulation, PP2Ac
overexpression, or treatment with the potent PP2A activator
forskolin (Feschenko et al., 2002) induced marked apoptosis,
reduced proliferation, impaired colony formation, inhibited tu-
morigenesis, and restored differentiation of BCR/ABL-trans-
formed cells regardless of their degree of sensitivity to imatinib
(note that also T315I BCR/ABL+ cells were inhibited by PP2A
activation). Because ectopic SET expression neutralized the tu-
mor-suppressive activity of PP2A both in vitro and in vivo, our
data indicate that the antileukemic effects of SET downregula-
tion are highly dependent on increased PP2A activity. However,
we cannot exclude that interference with the ability of SET to
regulate nucleosome assembly (Fan et al., 2003) and to func-
tion as an acetyltransferase inhibitor (Seo et al., 2001) might,
in part, account for the phenotype of shRNA-SET-expressing
cells.
Consistent with the effects of PP2A in BCR/ABL cell lines,
reestablishment of PP2A activity in myeloid CML-BCCD34+ cells
resulted in marked inhibition of proliferation and induction of
apoptosis (>95% annexin V+). Similarly, the clonogenic poten-
tial of CML-BCCD34+ cells was also dramatically reduced by
ectopic PP2A expression (90% inhibition) and by forskolin or
1,9-dideoxy-forskolin (lacks adenylate cyclase inducing activ-
ity) treatment (80%–95% inhibition). Interestingly, the clono-
genic potential of CML-CPCD34+ patient cells was also strongly
inhibited by activation of PP2A, consistent with the effect of
PP2A on signal transducers (e.g., Akt) essential for survival of
CML-CP progenitors. Importantly, in vivo administration of the
PP2A activators forskolin and/or 1,9-dideoxy forskolin severely
impacted and efficiently modulated the development of wild-
type and T315I BCR/ABL-induced acute leukemia-like disease
process, consistent with the reported ability of forskolin to pre-
vent tumor colonization and metastasis (Agarwal and Parks,
1983) and inhibit growth and induce apoptosis of myeloid and
lymphoid leukemic cells (Gutzkow et al., 2002; Moon and Ler-
ner, 2003; Taetle and Li-en, 1984). Remarkably, forskolin but
not its derivative, 1,9-dideoxy-forskolin, partially inhibited cy-
tokine-driven colony formation and proliferation of NBMCD34+
cells without inducing either apoptosis or PP2A activity. Thus,
the effects of forskolin on NBM cells most likely depend on its
ability to activate adenylate cyclase and induce cAMP (Sea-
mon and Daly, 1981), which inhibits cytokine-dependent prolif-
eration of normal myeloid progenitors (Derigs et al., 1989; Lu
et al., 1986). By contrast, the antileukemic effects of forskolin
appear to depend on induction of PP2A activity rather than
increased intracellular cAMP and/or PKA activation (Ding and
Staudinger, 2005), as exposure of BCR/ABL-transformed cells
to the cAMP inducer theophylline (Yasui et al., 1997) or to a
PKA inhibitor (Rimon and Rubin, 1998) did not alter BCR/ABL
expression/activity.
In summary, we showed that functional loss of PP2A tumor
suppressor activity occurs in myeloid CML-BC through the ef-
fect of BCR/ABL on SET expression and that reestablishment
of normal PP2A activity antagonizes both in vitro and in vivo
BCR/ABL leukemogenesis. Thus, enhancement of PP2A tumorCANCER CELL : NOVEMBER 2005suppressor activity may represent a novel therapeutic strategy
for blast crisis and imatinib-resistant CML patients.
Experimental procedures
Cell cultures and primary cells
The Ph1 K562, the BCR/ABL-expressing 32Dcl3 and BaF3 cells, and their
derivative lines were maintained in culture in IMDM/10% FBS/2 mM L-glu-
tamine. The SET shRNA-, HA-PP2Ac-, and HA-PP2Ac/FLAG-SET-express-
ing cells were generated by retroviral infection followed by either antibiotic-
mediated selection or FACS-mediated sorting of the GFP+ (green fluorescent
protein) cells as described (Perrotti et al., 2002). The following cells were
kind gifts: 32D-p210Y253H (B. Calabretta; TJU, Philadelphia, PA); BaF3-
p210T315I (B. Druker; OHSU, Portland, OR); TonB210.1 (G. Daley; Harvard
University, Cambridge, MA). Frozen samples of CD34+ bone marrow cells
(NBM) from different healthy donors were from AllCells LLC (Berkeley, CA).
Frozen samples of mononuclear hematopoietic cells from bone marrow or
peripheral blood of unidentifiable CML patients were Ficoll separated and
used for Western blot analysis or to isolate the CD34+ fraction by using the
CD34 MultiSort kit (Miltenyi Biotec). Before being used in the different as-
says, CD34+ NBM and CML cells were kept overnight in IMDM supple-
mented with 50% FBS, 2 mM glutamine, and rhIL-3 (20 ng/ml), rhIL-6 (20
ng/ml), rhFlt-3 ligand (100 ng/ml), and rhKL (100 ng/ml) (Stem Cell Technol-
ogies Inc.). Retroviral infection with MSCV-based GFP-containing bi-
cistronic constructs were carried out as described (Iervolino et al., 2002),
and infected cells were isolated by FACS-mediated sorting of GFP+ cells.
All studies performed with human specimens obtained from The Ohio State
University Leukemia Tissue Bank (Columbus, OH); from the Division of He-
matology, Maisonneuve-Rosemont Hospital (Montreal, Canada); and from
Dr. Gambacorti-Passerini (Division of Experimental Oncology, NCI Milan,
Italy) were done with approval from The Ohio State University Institutional
Review Board. The percentage of CML-CP Ph+ cells by FISH ranged from
91% to 100%. The CML-BC samples were all myeloid blast crisis and,
mostly, with complex karyotype; however, no one CML-BC presented dele-
tions of the der9q. Granulocytic differentiation of 32Dcl3-derivative cell lines
was induced as described (Perrotti et al., 2002). Erythroid differentiation of
K562 and derivative cell lines was assessed by o-Dianisidine (Fast Blue
B; Sigma) staining of methylcellulose colonies. Green/brown-stained cells
indicate presence of hemoglobin.
Normal murine hematopoietic marrow cells were obtained from the fe-
murs of wild-type and SHP-1-deficient “viable moth eaten” mice (The Jack-
son Laboratory). After hypotonic lysis and Ficoll separation, cells were used
for the isolation of the CD34+/lin− fraction (Miltenyi Biotech). CD34+ cells
were kept for 2 days in complete IMDM supplemented with murine IL-3 (2
ng/ml), IL-6 (1.2 ng/ml), and KL (10 ng/ml) prior to infection with MigRI or
MigRI-BCR/ABL (W. Pear, University of Pennsylvania, Philadelphia, PA).
GFP+ (Iervolino et al., 2002) wild-type and SHP-1−/− CD34+ cells (106) were
treated or not with forskolin (40 M; 48 hr) and used in clonogenic assay
or processed for Western blot. Where indicated, cells were treated with the
following: ALLN, okadaic acid, calyculin A, SS, and butyryl-forkolin (EMD
Bioscience Inc.); forskolin, 1,9-dideoxy-forskolin, and myristoylated PKI-
(14-22) amide (BioMol); imatinib (Novartis); and theophylline (Sigma). Cells
in liquid culture were treated with forskolin or imatinib at 40 M and 1 M,
respectively, and a half dose of forskolin or imatinib was added every 18 hr.
Plasmids
pHM6-HA-PP2Ac
pHM6-HA-PP2Ac contains the HA-tagged PP2A catalytic subunit under the
control of the CMV promoter (P.B. Rothman, Columbia University, New
York, NY).
MigRI-HA-PP2Ac
The HA-tagged PP2Ac cDNA was PCR amplified from pHM6-HA-PP2Ac
and subcloned into the HpaI/EcoRI sites of the bicistronic GFP-containing
MigRI vector.
pSuper.retro-shSET
The shRNA SET construct was obtained by subcloning the double-stranded
60 mer oligonucleotide containing the SET target sequence (5#-TGAAATA
GACAGACTTAAT-3#) into the pSuper.retro.neo+GFP vector (OligoEngine
Inc.).365
A R T I C L EMSCV-FLAG-SET
The human SET cDNA was obtained from K562 mRNA by RT-PCR using
an upstream primer containing a HpaI site, the FLAG epitope, and the first
16 nucleotides of SET cDNA, and a downstream primer containing the last
21 nucleotides of SET linked to an EcoRI restriction site. The HpaI/EcoRI-
digested PCR product was subcloned into the MSCV-puro vector.
RT-PCR of immunoprecipitated RNA
K562 cells (108) were lysed in 2 pellet/vol of 10 mM HEPES (pH 7.0), 100
mM KCl, 1 mM MgCl2, 1 mM DTT, 0.5% Nonidet P-40, 100 U/ml RNase
OUT (Invitrogen), 0.2 mM PMSF, 1 mg/ml pepstatin A, 5 mg/ml bestatin,
and 20 mg/ml leupeptin and clarified (100,000 × g, 2.5 hr). RNP-containing
particles were purified by centrifugation (300,000 × g; 3 hr) and resus-
pended in 1 ml of 50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM MgCl2, 0.05%
NP-40, 100 U/ml RNase OUT, 0.2 mM PMSF, and 20 mM EDTA. Immuno-
precipitation (IP) and extraction of the hnRNP A1 bound mRNA was per-
formed as described (Tenenbaum et al., 2002). The presence of SET tran-
scripts was assessed by RT-PCR performed on an equal amount of RNA,
extracted from RNP-enriched lysates (input) as well as from the hnRNP-A1
or FLAG immunoprecipitates. To amplify SET mRNA, the following primers
were used: 5#-GAGGTCAGAATTGATCGCCAAAATC-3# and 5#-TCAGATG
AAATTCTTTGGAGAGAAC-3#.
Northern blot analysis and RT-PCR
Total RNA was isolated using the acid phenol-guanidinium-mediated ex-
traction (Tri-Reagent; Invitrogen). For Northern blot, total RNA (5 g) was
hybridized to 32P-labeled hSET cDNA. To detect BCR/ABL transcripts, RNA
was extracted (QIAamp RNA blood kit; Qiagen) from mouse peripheral
blood (100 l). RNA from K562:32Dcl3 cells (ratio 1:106) served as positive
control, whereas RNA from blood of mice that were not injected with BCR/
ABL+ cells was used as negative control. Total RNA (1 g) was reverse
transcribed in 20 l, and cDNA (5 l) was used to detect BCR/ABL tran-
scripts by nested PCR using a first set of primers spanning the bcr exon
1/abl exon 3 and a second set amplifying a bcr exon 2/abl exon 3 fragment.
The nested RT-PCR conditions were previously described (Cross et al.,
1993). GAPDH levels were monitored as control for equal amplification.
Western blot analysis and IP
Cells (107) were lysed in 100 l of RIPA buffer (150 mM NaCl, 1% NP-40,
0.1% SDS, 50 mM Tris [pH 8.0]) supplemented with 1 mM PMSF, 25 g/ml
aprotinin, 10 g/ml leupeptin, 100 g/ml pepstatin A, 5 mM benzamidine,
1 mM Na3VO4, 50 mM NaF, 10 mM β-glycerol-phosphate. After incubation
on ice (30 min), lysates were clarified (12,000 × g, 15 min, 4°C), denatured,
and subjected to SDS-PAGE and Western blot (Iervolino et al., 2002). The
antibodies used were goat polyclonal anti-SET(I2PP2A), -pp32(I1PP2A),
and -hnRNP A1 and rabbit polyclonal anti-SHP-1 (Santa Cruz Biotechnol-
ogy); monoclonal anti-Abl (Ab-3), -c-myc (Ab-2), -phosphotyrosine PY20
(Ab-4), and -pBADS112 (Ab-1) (EMD); monoclonal anti-hnRNP A1 (9H10) (G.
Dreyfuss, University of Pennsylvania, Philadelphia, PA); monoclonal anti-
GRB2 and -Rb (BD TransLab Inc.); monoclonal anti-HA (Covance); mono-
clonal anti-PP2Ac, clone 1D6 (Upstate Inc.); monoclonal anti-FLAG, clone
M2 (Sigma); monoclonal anti-pERKT202/Y204 and rabbit polyclonal anti-
pAKTT308, -pSTAT5Y694, -pJak2Y1007/1008, -Jak2, -BAD, -Akt, and -ERK1/2
(Cell Signaling Technology Inc.); monoclonal anti-STAT5 (Invitrogen); rabbit
monoclonal anti-pPP2AY307 (Epitomics); rabbit polyclonal anti-PR65/A (Cal-
biochem). IPs were carried out in 20 mM HEPES (pH 7.0), 150 mM NaCl,
and 0.2% NP-40 supplemented with protease and phosphatase inhibitors.
Lysates were precleared and immunoprecipitated with Ab-coated beads for
3 hr at 4°C. After washings, IPs were subjected to SDS-PAGE and West-
ern blot.
Phosphatase assays
PP2A phosphatase assays were carried out using the PP2A IP phosphatase
assay kit (Upstate). Briefly, protein lysates (50 g) in 100 l of 20 mM
HEPES (pH 7.0)/100 mM NaCl, 5 g of PP2Ac antibody (Upstate), and 25
l of Protein A-agarose were added to 400 l of 50 mM Tris (pH 7.0)/100
mM CaCl2, and IPs were carried out at 4°C for 2 hr. IPs were washed and
used in the phosphatase reaction according to the manufacturer’s protocol.
Specificity of the PP2A assay was assessed by titration with okadaic acid
and by ascertaining the absence of PP1α in the PP2A immunoprecipitates366(Figure S2A). As internal control, the amount of immunoprecipitated PP2A
was also monitored by anti-PP2Ac Western blots (Figure S2B).
Clonogenic assays
Methylcellulose colony formation assays were carried out by plating 103 or
5 × 104 cells from BCR/ABL cell lines or primary human CML and mouse
BMC, respectively, in 0.9% MethoCult H4230 (Stem Cell Technologies Inc.).
Where indicated, cells were plated in the presence of rhIL-3 (100 ng/ml) or
rhG-CSF (25 ng/ml). Colonies (> 125 m) from cell lines and primary cells
were scored 7 and 15 days later, respectively.
Leukemogenesis in SCID mice
Parental cells and shRNA SET-, HA-PP2A-, and HA-PP2A/FLAG-SET-
expressing 32D-BCR/ABL cells were injected (5 × 106 cells/mouse) subcu-
taneously into 5-week-old SCID mice (Fox Chase SCID ICR; Taconic). Tu-
mor growth was monitored every other day. Mice were sacrificed 15 days
postinjection, and excised tumors were fixed in phosphate-buffered forma-
lin. To determine the effect of forskolin and 1,9-dideoxy forskolin on in vivo
BCR/ABL leukemogenesis, 6-week-old SCID mice were i.v. injected with
5 × 105 32D-BCR/ABL or 32D-BCR/ABL (T315I) cells (10 to 13 mice/group)
and treated with forskolin (100 g/ml of 2% DMSO/PBS) or 1,9-dideoxy
forskolin (200 g/ml of 2% DMSO/PBS) using the indicated schedule. Age-
matched mice or mice injected with cells or drugs only (6 to 7 mice) served
as controls. Four weeks postinjection, 2 to 3 mice from each group were
sacrificed, and organs were analyzed for the presence of leukemia. At the
indicated times, the disease process was monitored by nested RT-PCR-
mediated BCR/ABL detection using peripheral blood collected by lateral
tail-vein incision. For pathological examination, tissue sections from bone
marrow, spleen, and liver were fixed in formalin, embedded in paraffin
blocks, and hematoxylin/eosin stained. The remaining mice were used for
survival studies, which were terminated 15–18 weeks postinjection. The
in vitro and in vivo animal studies were conducted with the approval of the
Ohio State University Institutional Lab Animal Care and Use Committee and
in accordance with the National Institute of Health guidelines for animal
care.
Supplemental data
The Supplemental Data include four supplemental figures and can be found
with this article online at http://www.cancercell.org/cgi/content/full/8/5/355/
DC1/.
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